The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Extending remission in patients with AML who become eligible for alloSCT following targeted therapy
Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, discusses current and future optimal treatment strategies for extending remission in patients with acute myeloid leukemia (AML) who are ineligible for chemotherapy but become eligible for allogeneic stem cell transplantation (alloSCT) following treatment with targeted therapies. At present, therapeutic strategies, such as a triplet regimen of gilteritinib, azacitidine, and venetoclax, are being investigated for prolonging and deepening remission in this patient population. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: AbbVie, Allogene, AstraZeneca, Genentech, Gilead, ImmunoGen, MEI Pharma, Precision, Rafael, Sanofi, Stemline; Advisory/Consulting: AbbVie, AstraZeneca, Auxenion, Bakx, Boehringer, Dark Blue Therapeutics, F. Hoffman La-Roche, Genentech, Gilead, Janssen, Legend, MEI Pharma, Redona, Sanofi, Sellas, Stemline, Vincerx; Stock options/Royalties: Reata Pharmaceutical (IP); Patent: Novartis, Eli Lilly, Reata Pharmaceutical.
